England and Wales’ cost effectiveness watchdog NICE has rejected Opdivo for use against advanced head and neck cancer in draft guidance – before the drug has even been given final Euro
The Conference Forum is delighted to present the 2nd annual Rational Combinations 360°, the only event addressing business aspects, novel clinical trial designs and scientific deve
